BETHESDA, Md., Sept. 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and webcast on September 22, 2009 at 7:00 am U.S. Eastern Time to discuss the data from a phase 1 clinical trial with Micromet's anti-EpCAM BiTE antibody MT110, which was presented on September 21, 2009 at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany. The webcast will be available on the company's website at www.micromet-inc.com.
Forum: Micromet, Inc. Conference Call and Webcast Date: Tuesday, September 22, 2009 Time: 7:00 am to 7:30 am U.S. Eastern Time Webcast: www.micromet-inc.com
To participate in this conference call, dial 1-866-314-9013 (U.S.) or 1-617-213-8053 (international), passcode: 47917462. The audio webcast can be accessed at www.micromet-inc.com.
A replay of the call will be available from 9:00 am U.S. Eastern Time on September 22, 2009 (3:00 pm Central European Time) through, September 29, 2009. The replay number is 1-888-286-8010 (U.S.) or 1-617-801-6888 (international), passcode: 74744916.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.
This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of Micromet's BiTE antibody MT110, which targets the epithelial cell adhesion molecule (EpCAM), currently in a phase 1 clinical trial for the treatment of patients with solid tumors, and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2009, filed with the SEC on August 6, 2009, as well as other filings by the company with the SEC.
|SOURCE Micromet, Inc.|
Copyright©2009 PR Newswire.
All rights reserved